Although prostate-specific antigen (PSA) represents the first step in a risk-adapted strategy, it is well known that PSA lacks specificity in PCa diagnosis as this biomarker is organ specific, but not cancer specific. This evidence concerns the gene KLK3 and posterior cortical atrophy.